Výsledky vyhledávání - "Hanae Suzuki"

Coincidence of Sarcoidosis and a COVID-19 vaccine-associated hypermetabolic lymphadenopathy in a patient with a history of invasive breast cancer: A case report

Autor: Asuka Kawabata, Toru Nakamura, Hanae Suzuki, Masayuki Yoshida, Yoshiro Otsuki, Natsuko Mori

Publikováno v: International Journal of Surgery Case Reports. 94:107098

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::488229bcc827a48ba9374c30d96e38c7
https://doi.org/10.1016/j.ijscr.2022.107098

Zobrazit plný text záznamu

Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer

Autor: Hanae Suzuki, Takashi Miyamoto, Ayako Tatsuguchi, Yusuke Nakamura, Yo Matsuo, Naofumi Takamatsu, Suyoun Chung, Koji Ueda, Kyoko Kijima

Publikováno v: Oncotarget

// Suyoun Chung 1 , Hanae Suzuki 2 , Takashi Miyamoto 2 , Naofumi Takamatsu 2 , Ayako Tatsuguchi 3 , Koji Ueda 3 , Kyoko Kijima 2 , Yusuke Nakamura 1,4 and Yo Matsuo 2 1 Department of Medicine and Surgery, The University of Chicago, Chicago, IL, USA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1e1c1289eaf35a1920c797942bd04b2
https://doi.org/10.18632/oncotarget.790

Zobrazit plný text záznamu

Orally administrative melk (maternal embryonic leucine zipper kinase)-targeting small molecule inhibitor suppresses the growth of various types of human cancer

Autor: Hanae Suzuki, Takashi Miyamoto, Suyoun Chung, Koji Ueda, Ayako Tatsuguchi, Kyoko Kijima, Naofumi Takamatsu, Yusuke Nakamura, Yo Matsuo

Publikováno v: Journal of Clinical Oncology. 31:e13569-e13569

e13569 Background: We previously reported MELK (maternal embryonic leucine zipper kinase) as a novel therapeutic target for breast cancer. MELK was also highly upregulated in multiple types of cancer including prostate, pancreas and lung cancers, and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::666663c5d8d57b1c8943411a910aab53
https://doi.org/10.1200/jco.2013.31.15_suppl.e13569

Zobrazit plný text záznamu

Abstract LB-300: Development of an orally-administrative MELK (maternal embryonic leucine zipper kinase)-targeting small molecule inhibitor that suppresses the growth of various types of human cancer

Autor: Takashi Miyamoto, Hanae Suzuki, Naofumi Takamatsu, Kyoko Kijima, Koji Ueda, Yo Matsuo, Suyoun Chung, Ayako Tatsuguchi, Yusuke Nakamura

Publikováno v: Cancer Research. 73:LB-300

Breast cancer is the most common malignancy among women worldwide. Treatment for breast cancer acting on molecular targets in critical signaling pathways in cancer cells have successfully reduced the motility rate in a subset of breast cancer patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c210a2eda2f50d5cfef7319fe855016d
https://doi.org/10.1158/1538-7445.am2013-lb-300

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání